Miconal

Miconazole nitrate, the active ingredient in Miconal, is an imidazole antifungal presented as a vaginal formulation for local use. It is indicated for the treatment of vulvovaginal candidiasis, a common yeast infection affecting women of reproductive age. By inhibiting fungal ergosterol synthesis, the product helps to eradicate Candida species and relieve associated symptoms such as itching, burning, and abnormal discharge.

GNH USA supplies Miconal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with reliable quality assurance and regulatory compliance.

Miconal is used to treat fungal infections of the vaginal tract, specifically candidal overgrowth.

Vulvovaginal candidiasis: eliminates Candida species, reduces itching, burning and discharge, and helps restore normal vaginal flora.

Miconal may cause local adverse reactions in the vaginal area, ranging from mild irritation to rare severe events.

Common Side Effects: - Vaginal itching or pruritus - Burning sensation during or after application - Local irritation or redness - Increased vaginal discharge or spotting

Serious or Rare Side Effects: - Allergic reaction such as rash, hives, or swelling - Severe skin reactions including Stevens‑Johnson syndrome - Angioedema affecting face, lips, or throat - Systemic hypersensitivity with fever or malaise

Before using Miconal, consider the following precautions to ensure safe and effective treatment.

Pregnancy: consult a healthcare professional before use. Breastfeeding: discuss potential risks with a physician. Allergy: avoid if known hypersensitivity to miconazole or other imidazoles. Concomitant vaginal products: do not use other intravaginal medications simultaneously. Hepatic impairment: use with caution in patients with liver disease. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Miconal can interact with other medicines; awareness of major and moderate interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic absorption of miconazole. - Warfarin: may enhance anticoagulant effect, requiring closer monitoring.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may have reduced efficacy; advise backup contraception. - Systemic azoles (e.g., fluconazole): may increase cumulative antifungal exposure. - Antacids containing aluminum or magnesium: may alter local pH and affect drug release.